@article {7622,
	title = {The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma},
	journal = {Leukemia},
	volume = {27},
	year = {2013},
	note = {Cited By :55Export Date: 21 February 2017},
	month = {2013},
	pages = {423 - 429},
	abstract = {The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. A significant improvement of renal function (>=renalPR (renal partial response)) was observed in 77\% of patients treated with bortezomib, in 55\% with thalidomide and in 43\% with lenalidomide (P=0.011). In multivariate analysis, bortezomib-based therapy was independently associated with a higher probability of renal response compared with thalidomide-or lenalidomide-based therapy. Other important variables included eGFR (estimated glomerular filtration rate) >=30 ml/min, age <=65 years and myeloma response. Patients treated with bortezomib achieved at least renalPR in a median of 1.34 months vs 2.7 months for thalidomide and >6 months for lenalidomide-treated patients (P=0.028). In multivariate analysis bortezomib-based therapy, higher doses of dexamethasone (>=160 mg during the first month of treatment), an eGFR >=30 ml/min and age <=65 years were independently associated with shorter time to renal response. In conclusion, bortezomib-based therapies may be more appropriate for the initial management of patients with myeloma-related renal failure; however, thalidomide and lenalidomide are also associated with significant probability of improvement of their renal function. {\textcopyright} 2013 Macmillan Publishers Limited All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873569016\&doi=10.1038\%2fleu.2012.182\&partnerID=40\&md5=e2d9cf2b822b78c6d838f1cb183eebcb},
	author = {Dimopoulos, M.A. and Roussou, M. and Gkotzamanidou, M. and Nikitas, N. and Psimenou, E. and Mparmparoussi, D. and Matsouka, C. and Spyropoulou-Vlachou, M. and Terpos, E. and Kastritis, E.}
}
